BiotechTube

Lenvatinib + Pembrolizumab + Paclitaxel + Carboplatin

Phase 3Completed
0 watching 0 views this week📈 Rising
77
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Endometrial Neoplasms

Conditions

Endometrial Neoplasms

Trial Timeline

Oct 22, 2019 → Jan 14, 2025

NCT ID
NCT04865289

About Lenvatinib + Pembrolizumab + Paclitaxel + Carboplatin

Lenvatinib + Pembrolizumab + Paclitaxel + Carboplatin is a phase 3 stage product being developed by Eisai for Endometrial Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT04865289. Target conditions include Endometrial Neoplasms.

Hype Score Breakdown

Clinical
27
Activity
18
Company
10
Novelty
9
Community
10

Clinical Trials (2)

NCT IDPhaseStatus
NCT04865289Phase 3Completed
NCT03884101Phase 3Completed

Competing Products

20 competing products in Endometrial Neoplasms

See all competitors
ProductCompanyStageHype Score
Atezolizumab - 28 Day Cycle + Bevacizumab + Ipatasertib + Talazoparib + Trastuzumab emtansine + Tiragolumab + Atezolizumab - 21 Day Cycle + Inavolisib + Letrozole + Giredestrant + AbemaciclibEli LillyPhase 1/2
41
ACR-368 + GemcitabineAcrivon TherapeuticsPhase 2
44
Sodium Cridanimod + progestin therapyXenetic BiosciencesPhase 2
44
Letrozole + Abemaciclib + LY3023414 + Metformin + Zotatifin + GedatolisibeFFECTOR TherapeuticsPhase 2
44
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Trastuzumab deruxtecan + Rilvegostomig + Pembrolizumab + Carboplatin + Paclitaxel + DocetaxelDaiichi SankyoPhase 3
77
Trastuzumab Deruxtecan + ChemotherapyDaiichi SankyoPhase 3
77
Datopotamab deruxtecan (Dato-DXd) + Capecitabine + 5-Fluorouracil + Volrustomig + Carboplatin + Bevacizumab + Rilvegostomig + Prednisone/ prednisolone + CisplatinDaiichi SankyoPhase 2
52
Trastuzumab deruxtecanDaiichi SankyoPhase 2
52
Enfortumab VedotinAstellas PharmaPhase 2
52
LenvatinibEisaiPhase 2
52
Pembrolizumab + Lenvatinib + Paclitaxel + DoxorubicinEisaiPhase 3
77
Lenvatinib + Pembrolizumab + Paclitaxel + CarboplatinEisaiPhase 3
77
E7386 + Lenvatinib + Doxorubicin + PaclitaxelEisaiPhase 1/2
41
Abemaciclib + LetrozoleEli LillyPhase 2
52
Abemaciclib + Anastrozole + LetrozoleEli LillyPhase 2
52
LY3023414Eli LillyPhase 2
52
arzoxifene hydrochlorideEli LillyPhase 2
52
Abemaciclib + Letrozole + PembrolizumabEli LillyPhase 2
52
Trabectedin + DexamethasoneJohnson & JohnsonPhase 2
52

Other Products from Eisai

MecobalaminApproved
85
MonteplaseApproved
85
E2020 + PlaceboApproved
85
Palonosetron 0.075 mg IV + Dexamethasone 10 mg IV + Promethazine 25 mg IVApproved
85
DonepezilApproved
85